Cardiometabolic syndrome is a combination of metabolic dysfunction mainly characterized by insulin resistance, impaired glucose metabolism, dyslipidemia, and hypertension. Cardiac remodeling, coronary heart disease, and even heart failure could result from metabolic syndrome. Currently, around 25% of the adults worldwide are suffering from this syndrome. Along with the increased rates of obesity, diabetes and hypertension in the past decades, there has been an increase in the incidence of CMS. With these standard risk factors, the scientific research aims to focus on addressing the diverse constellation of risk factors and identifying new diagnostic biomarkers that incorporates an integrated approach to treating these risk factors across diverse populations. In this session, the pathophysiology, risk assessment for precision health, molecular and metabolic biomarkers of metabolic cardiovascular disease, especially posttranslational modification of troponin will be presented and discussed.

Learning Objectives:

• Pathophysiology of cardiovascular consequence of metabolic syndrome
• Molecular insights in metabolic cardiovascular disease
• Risk assessment, metabolic biomarkers and the evolution of proteomic troponin analysis for predicting CMS